Gå till forskningen.

Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.

Publikationer som ChEBI hänvisar till för N-(5-\{[(5-tert-butyl-1,3-oxazol-2-yl)methyl]sulfanyl\}-1,3-thiazol-2-yl)piperidine-4-carboxamide. Visa hela publikationsregistret

En publikationsträff är inte en slutsats. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.

Publikationer i urvalet

7 träffar

Bibliografisk träff 2015-09-02

Correction to N-(Cycloalkylamino)acyl-2-aminothiazole Inhibitors of Cyclin-Dependent Kinase 2. N-[5-[[[5-(1,1-Dimethylethyl)-2-oxazolyl]methyl]thio]-2-thiazolyl]-4-piperidinecarboxamide (BMS-387032), a Highly Efficacious and Selective Antitumor Agent.

Misra RN, Xiao HY, Kim KS, Lu S, Han WC, Barbosa SA, Hunt JT, Rawlins DB, Shan W, Ahmed SZ, Qian L, Chen BC, Zhao R, Bednarz MS, Kellar KA, Mulheron JG, Batorsky R, Roongta U, Kamath A, Marathe P, Ranadive SA, Sack JS, Tokarski JS, Pavletich NP, Lee FY, Webster KR, Kimball SD.

J Med Chem · published erratum · DOI 10.1021/acs.jmedchem.5b01294

Bibliografisk träff 2015-05-19

Interactions of cyclin-dependent kinase inhibitors AT-7519, flavopiridol and SNS-032 with ABCB1, ABCG2 and ABCC1 transporters and their potential to overcome multidrug resistance in vitro.

Cihalova D, Staud F, Ceckova M.

Cancer Chemother Pharmacol · research support, non-u.s. gov't; journal article · DOI 10.1007/s00280-015-2772-1

Bibliografisk träff 2015-03-01

[Apoptosis of acute myeloid leukemia HL-60 cells induced by CDK inhibitor SNS-032 and its molecular mechanisms].

Han YX, You LS, Liu H, Mao LP, Ye XJ, Qian WB.

Zhejiang Da Xue Xue Bao Yi Xue Ban · research-article; journal article · DOI 10.3785/j.issn.1008-9292.2015.03.009

Bibliografisk träff 2013-06-01

[Effect of SNS-032 on biological activity of hematopoietic stem cells in mice].

Qi RZ, Ji Q, Zhang LY, Zhang Y, Yuan WP, Cheng T, Gao YD, Xu J.

Zhongguo Shi Yan Xue Ye Xue Za Zhi · research support, non-u.s. gov't; journal article; english abstract · DOI 10.7534/j.issn.1009-2137.2013.03.040

Bibliografisk träff 2011-01-07

The cyclin-dependent kinase inhibitor SNS-032 has single agent activity in AML cells and is highly synergistic with cytarabine.

Walsby E, Lazenby M, Pepper C, Burnett AK.

Leukemia · journal article · DOI 10.1038/leu.2010.290

Bibliografisk träff 2009-01-24

SNS-032 is a potent and selective CDK 2, 7 and 9 inhibitor that drives target modulation in patient samples.

Conroy A, Stockett DE, Walker D, Arkin MR, Hoch U, Fox JA, Hawtin RE.

Cancer Chemother Pharmacol · clinical trial, phase i; journal article · DOI 10.1007/s00280-008-0921-5

Bibliografisk träff 2007-10-16

A phase 1 study of SNS-032 (formerly BMS-387032), a potent inhibitor of cyclin-dependent kinases 2, 7 and 9 administered as a single oral dose and weekly infusion in patients with metastatic refractory solid tumors.

Heath EI, Bible K, Martell RE, Adelman DC, Lorusso PM.

Invest New Drugs · clinical trial, phase i; journal article · DOI 10.1007/s10637-007-9090-3